Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 17/20 | 0.65 |
| ▸ | TACR1 | P25103 | 15/20 | 0.65 |
| ▸ | TACR3 | P29371 | 8/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | CCR5 | P51681 | 2/20 | 0.57 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5677576 | 1.00 | TACR2 (0.65) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL7751540 | 0.97 | TACR2 (0.61) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL6951866 | 0.94 | TACR2 (0.62) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL24855520 | 0.92 | TACR2 (0.61) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL31224112 | 0.92 | TACR2 (0.61) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL7380394 | 0.92 | TACR2 (0.61) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL7307273 | 0.91 | TACR2 (0.54) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL8204438 | 0.89 | TACR2 (0.67) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL8349879 | 0.89 | TACR2 (0.60) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL6543332 | 0.87 | TACR2 (0.64) | TACR2TACR1TACR3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073838-A1 | 3-alkyl-3-phenyl-piperidines | CHEN MICHAEL HUAI GU (US) | 2003-04-17 | — | — | US | claimed |
| US-20010037023-A1 | 3-alkyl-3-phenyl-piperidines | CHEN MICHAEL HUAI GU (US) | 2001-11-01 | — | — | US | claimed |
| US-6602886-B2 | 3-alkyl-3-phenyl-piperidines | WARNER-LAMBERT COMPANY | 2003-08-05 | — | — | US | disclosed |
| US-20030073838-A1 | 3-alkyl-3-phenyl-piperidines | CHEN MICHAEL HUAI GU (US) | 2003-04-17 | — | — | US | disclosed |
| US-6433178-B2 | ALKYL PYRIMIDINES SUBSTITUTED PIPERIDINE DERIVATIVES ARE USED AS TACHYKININ ANTAGONSIT, USEFUL IN THE TREATMENT OF PAIN, DEPRESSION, ANXIETY, PANIC, SCHIZOPHRENIA, NEURALGIA, ADDICTION DISORDER, INFLAMMATION, AND NEUROLOGICAL DISORDERS | WARNER-LAMBERT COMPANY | 2002-08-13 | — | — | US | disclosed |
| US-20010037023-A1 | 3-alkyl-3-phenyl-piperidines | CHEN MICHAEL HUAI GU (US) | 2001-11-01 | — | — | US | disclosed |
| US-6040316-A | TACHYKININ ANTAGONISTS TREATING PAIN, DEPRESSION, ANXIETY, PANIC, SCHIZOPHRENIA, NEURALGIA, ADDICTION DISORDERS, INFLAMMATORY DISEASES, GASTROINTESTINAL DISORDERS, VASCULAR DISORDERS, AND NEUROPATHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY (US) | 2000-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037023-A1 | 3-alkyl-3-phenyl-piperidines | TAC3, KCNK3, ACKR3 | TACR2 10/4885TACR1 21/4885TACR3 22/4885 |
| US-20030073838-A1 | 3-alkyl-3-phenyl-piperidines | TAC3, KCNK3, ACKR3 | TACR2 10/4885TACR1 21/4885TACR3 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.